ESTRO 2022 | Acute toxicity data from the PEACE V: STORM trial

Name: Acute toxicity data from the PEACE V: STORM trial
Uploaded: 2022-05-23T00:00:00Z
Duration: 2 min 22 s

Thomas Zilli • 23 May 2022

ESTRO 2022

PEACE V - STORM

Thomas Zilli, MD, Geneva University Hospitals, Geneva, Switzerland, discusses the acute toxicity data from the PEACE V: STORM trial (NCT03569241), which aimed to identify the best treatment strategy for patients with oligorecurrent nodal prostate cancer. Eligible patients had up to 5 nodal lesions, assessed by PET-CT scanning. Patients were randomised to either the control arm, in which they received 6 months of androgen deprivation therapy (ADT) plus either salvage lymph node dissection or stereotactic body radiotherapy (SBRT), or to the experimental arm, in which they received whole pelvic radiotherapy plus 6 months of ADT plus either salvage lymph node dissection or SBRT. The primary endpoint was metastases-free survival. The acute toxicity data reported that the treatments in both arms of the trial were well-tolerated. This interview took place at the European Society for Radiotherapy and Oncology (ESTRO) 2022 annual congress in Copenhagen, Denmark, and online.